Natural History Study of Patients With Neurofibromatosis Type I
Active not recruiting
259 enrolled
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Phase 2 Completed
75 enrolled 17 charts
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Phase 2 Completed
11 enrolled 11 charts
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase 1 Completed
29 enrolled
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Phase 2 Completed
30 enrolled 19 charts
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase 1 Completed
55 enrolled
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Phase 1 Terminated
129 enrolled
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase 1 Completed
72 enrolled
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Phase 1 Completed
24 enrolled
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Phase 1 Completed
45 enrolled
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Phase 1 Completed
55 enrolled
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
Phase 1 Unknown
24 enrolled
Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer
Phase NA Unknown
50 enrolled
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
Phase 1 Unknown
48 enrolled
Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma
Unknown
900 enrolled
Lobradimil and Carboplatin in Treating Children With Brain Tumors
Phase 2 Completed
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Phase 1 Completed
36 enrolled
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase 2 Completed
200 enrolled
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled
ABT-751 in Treating Young Patients With Refractory Solid Tumors
Phase 1 Completed
90 enrolled
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
Phase 1 Completed
26 enrolled